Bipolar I disorder
is the most severe; it is characterized by manic episodes that last for at least a week and depressive episodes that last for at least 2 weeks.
Lundbeck today announced results from an international study of people living with bipolar I disorder
, which found a significant proportion of patients experience symptoms of depression during an episode of mania.
Throughout their lives, patients with bipolar I disorder
experience depressive symptoms approximately three times longer than manic symptoms.
The epidemiology of DSM-III-R bipolar I disorder
in a general population survey.
Just under 3 per cent of Canadians aged 25 to 46 years have experienced at least one manic episode suggestive of Bipolar I Disorder
according to the data from the 2002 Canadian Community Health Survey: Mental Health and Well-being.
5% were diagnosed with bipolar I disorder
, and took place during November and December 2011.
SEROQUEL XR is indicated for the treatment of acute depressive episodes associated with bipolar disorder, acute manic or mixed episodes associated with bipolar I disorder
as monotherapy and as an adjunct to lithium or divalproex; maintenance treatment of bipolar I disorder
as adjunct therapy to lithium or divalproex, and acute and maintenance treatment of schizophrenia.
SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder
a privately held human biobank based in the San Diego area, today announced the launch of its new PrecisionMed Sample Bank collection of DNA, RNA, plasma, serum and urine from 200 subjects with Bipolar I Disorder
and 200 matched controls.
and her colleagues at Ludwig-Maximilians-Universitat Munich evaluated 65 patients with bipolar I disorder
, 38 with bipolar II disorder, and 62 healthy controls using the Structured Clinical Interview for DSM-IV and a other tools (Bipolar Disord.
In the first randomized double-blind comparison of the efficacy and safety of Zyprexa and lithium in the prevention of bipolar episode relapse, patients diagnosed with bipolar I disorder
, who had at least two manic or mixed episodes within six years and a YMRS total score greater than or equal to 20, received open label combination therapy of Zyprexa and lithium for six to 12 weeks.
7% of patients with bipolar I disorder
, and depressive mixed states presented in 25.
A new option in the long-term treatment of bipolar I disorder
came in June 2003 with the U.
Food and Drug Administration (FDA) has approved Zyprexa(R) (olanzapine) for use in combination with lithium or valproate (Depakote(R), Abbott) for the treatment of acute manic episodes associated with bipolar I disorder
Overall, the registry's bipolar disorder population had a mean age of 53 years and was 89% male and 71% white; 84% had bipolar I disorder